Egetis concludes that demonstrating treatment effects on T3

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US •                       Emcitate® (tira...

Related Keywords

Stockholm , Sweden , United States , Netherlands , United Kingdom , America , J Clin Endocrinol , Mary Clark Manel Mateus , Nicklas Westerholm , Strategic Communications , European Medicines Agency , Erasmus Medical Center , Drug Administration , Fast Track , Pediatric Disease Priority Review Voucher , Nasdaq Stockholm , New Drug Application , Fast Track Designation , Marketing Authorisation Application , Triac Trial , Orphan Drug Designation , Rare Pediatric Disease Designation , Lancet Diabetes , Clinical Endocrinology , North America , Diabetes Endocrinol , Egetis Therapeutics ,